News | July 02, 2022
Lonza to invest 500 mn in commercial drug product fill & finish facility
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
It is a two dose vaccine to be administered intramuscularly at 28 days apart
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Company hires life science veteran Jessica Cao to join management team
States have an important role in ensuring food safety and healthy food practices.
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Innate to receive $5M milestone payment from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
